Whilst sitting in a famous Kingstown bar at the weekend, I listened while the owner, who sat with the customers, said how he was reliably told that the Heberprot-P medicine for diabetic foot ulcers was being held back in SVG now for the last two years, the product to be released at the next general election. Vincentians were not having their feet saved because this was an important ULP election tool.
When he was asked how he knew such information, he said some ULP politicians have loose mouths when they are full of rum.
So I came home and looked at the current distribution once again; even Antigua is about to get a supply, and most of the rest of the world already has it.
Belarus Purchases Cuban Medicine Heberprot-P
Prensa Latina, Friday 1st November, 2013. Minsk, Nov 1 (Prensa Latina) Belarus will apply Cuban unique drug worldwide to heal diabetic foot Heberprot-P, according to an agreement signed here, highlighted the Belarusian media. Doctor Luis Herrera, director of the Genetic Engineering and Biotechnology Center (CIGB) in Havana and acting minister of the pharmaceutical company Belmedpreparaty (BMP), Alexander Griegoriev, signed the document. Cuban angiologists will arrive in Minsk to train local doctors in the use of this biological medicine for the healing of advanced skin lesions and with high risk of amputation provoked by Mellitus Diab
Cuban Diabetic Foot Drug Launches in New markets
20.11.2013. HAVANA, Cuba (ACN) -- Cuba’s Genetic Engineering and Biotechnology Centre will launch its diabetic foot ulcer pharmaceutical known as Heberprot-P into new markets, such as Brazil, Peru and some European countries.
Heberprot-P was approved five years ago and over this period it has been commercialized in 18 countries, including Venezuela, Bolivia and Ecuador.
Cuba’s Heberprot-P Prevents Amputations in 3,000 Venezuelan Patients
2012.06.28 - 09:33:19 / firstname.lastname@example.org Cuba- HAVANA, The use, free of charge, of the Cuban medicament Heberprot-P has saved over 3,000 patients in the state of Falcon, Venezuela, from the amputation of their lower limbs.Developed in Cuba by the Center for Genetic Engineering and Biotechnology, this product began to be used in Venezuela by way of a program to reduce complications in diabetic foot patients and of bilateral health agreements, the www.cubaminrex.cu Web site reported on Wednesday. Heberprot-P has benefited over 30,000 Venezuelan patients, thanks to its property of favoring fast cicatrization of advanced lesions. This medicine has won the Gold Medal of the World Intellectual Property Organization (WIPO), and has been applied with notable results on more than 66,000 people from all parts of the world, with 90% average effectiveness.
Biotecnología Aplicada versión ISSN 1027-2852. Biotecnol Apl vol.30 no.1 La Habana ene.-mar. 2013
II International congress addressed to the integral care of diabetic foot ulcer patient with the use of Heberprot-P 2012
The second edition of the international congress addressed to the Integral care of diabetic foot patient with the use of Heberprot-P was successfully celebrated last December 12-14th, at the Memories Varadero hotel, in Cuba. Up to 500 delegates from 37 countries attended and were pleased with the update in the treatment of diabetic foot ulcers (DFUs) with Heberprot-P and strategies for the integral care of diabetic patients. The meeting counted on with several world leaders in DFU treatment. During the three working days, 11 plenary lectures, 31 oral presentations and 130 posters were discussed. Main topics comprised the mechanisms of wound healing using the human epidermal growth factor and its safety for DFU therapy. The use of Heberprot-P in Cuban patients as part of the nationwide integral care program for the treatment of DFUs was highlighted. This program have been extended to 43 major hospitals and 197 local clinics, with more than 15 000 patients treated and diminishing amputation rates in more than 65 %. This is a remarkable result considering that Heberprot-P successfully targets and generally cicatrizes complex Wagner 3-5 ulcers, mainly ischemic.
New markets for Heberprot-P
'OnCuba' Magazine 27 September, 2013 New pharmaceutical markets in America and Europe are open to the drug Heberprot-P, Cuban patent used in the treatment of diabetic foot ulcers, as announced during the XXIV International Congress of Orthopedics and Traumatology trade fair, held at the Frank País International Orthopedic Science Complex in Havana. Maylyn Palmero, product developer, said that in countries such as Brazil and Peru they are negotiating the terms of their marketing, supported by the international experience of the drug, as this has already been used in 125,000patients outside Cuba, out of which 100,000 are Venezuelans. Palmero told Cuban News Agency that Russia is very interested in this drug, which has no competition in the market because it is the only thing keeping the partial or total amputation of the affected area, since ulcer penetrates and gets the reconstitution of tissues from the inside out.
The failure to launch Heberprot-P in SVG two years ago is a very good reason not to re-elect the Marxist led ULP party.
Just watch our hospital and clinics fill with drugs and dressings as we approach the elections, it’s a disgrace. If you go into hospital now and have no money, you are as good as dead. Because your family will have to search the local pharmacies for whatever drugs and dressings you require. Even shipping some drugs in from Miami.
It’s time for the Unity Labour Party to go, and it’s time for the Cubans to go home.
Self Appointed Keeper of the Whistle